| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
ALK-4290 manufacturers
- ALK4290
-
- $1520.00
-
2026-07-27
- CAS:1251528-23-0
- Purity:
- Supply Ability: 10g
|
| | ALK-4290 Basic information |
| Product Name: | ALK-4290 | | Synonyms: | ALK-4290;BI-144807;4-Pyridinecarboxamide, 2-[[[(2R)-1-[1-[(4-chloro-3-methylphenyl)methyl]-4-piperidinyl]-5-oxo-2-pyrrolidinyl]carbonyl]amino]-N,N,6-trimethyl-;AKST-4290;2-[[[(2R)-1-[1-[(4-Chloro-3-methylphenyl)methyl]-4-piperidinyl]-5-oxo-2-pyrrolidinyl]carbonyl]amino]-N,N,6-trimethyl-4-pyridinecarboxamide (ACI) | | CAS: | 1251528-23-0 | | MF: | C27H34ClN5O3 | | MW: | 512.04 | | EINECS: | | | Product Categories: | | | Mol File: | 1251528-23-0.mol |  |
| | ALK-4290 Chemical Properties |
| Boiling point | 743.8±60.0 °C(Predicted) | | density | 1.288±0.06 g/cm3(Predicted) | | pka | 11.94±0.20(Predicted) | | form | Solid | | color | White to off-white |
| | ALK-4290 Usage And Synthesis |
| Uses | ALK4290 (AKST4290) is a potent and orally active CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a Ki of 3.2 nM for hCCR3[1]. ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism[2][3]. | | IC 50 | CCR3: 3.2 nM (Ki) | | References | [1] NIVENS MC, et, al. Use of ccr3-inhibitors. US20130261153A1.
[2] Samanta A, te, al. Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020. Asia Pac J Ophthalmol (Phila). May-Jun 2020; 9(3):250-259. DOI:10.1097/APO.0000000000000291
[3] Clinical Development of AKST4290 as a Novel Parkinson’s Therapeutic |
| | ALK-4290 Preparation Products And Raw materials |
|